Prostate cancer remains one of the most significant health challenges facing men in Aotearoa New Zealand. It is the most commonly diagnosed cancer among men and the second leading cause of male cancer deaths after lung cancer. Every year, more than 4,000 New Zealand men are diagnosed with prostate cancer and more than 700 lose their lives to the disease.
Yet behind these national statistics lies a stark and troubling reality: Māori men are disproportionately affected by poor outcomes, despite being diagnosed less frequently than non-Māori men.
Health experts, researchers and advocates say the issue is not simply about cancer itself. It is about inequities in healthcare access, systemic barriers, delayed diagnoses and a lack of culturally responsive services that continue to place Māori men at greater risk.
The prostate is a small gland located below the bladder in men. Prostate cancer develops when abnormal cells grow uncontrollably within the gland.
One of the challenges of prostate cancer is that it often develops slowly and may show no symptoms during its early stages. As the disease progresses, symptoms can include:
- Difficulty urinating
- Frequent urination, particularly at night
- Blood in urine or semen
- Pain in the pelvis or lower back
- Erectile dysfunction
- Unexplained weight loss and fatigue in advanced cases
Because symptoms often do not appear until the disease has progressed, early detection is considered one of the most effective ways to improve survival rates.
The Māori Health Disparity
Research consistently shows Māori men experience worse prostate cancer outcomes than non-Māori men.
While Māori men are approximately 20 percent less likely to be diagnosed with prostate cancer, they are significantly more likely to die from the disease. Some studies suggest Māori men are up to 50 percent more likely to die following a prostate cancer diagnosis.
This apparent contradiction points to a deeper issue.
Health researchers have found Māori men are more likely to be diagnosed when cancer has already reached an advanced or metastatic stage, reducing treatment options and lowering survival rates.
The lower diagnosis rate does not necessarily mean Māori men are less affected by prostate cancer. Instead, it may indicate that cancers are being detected later, or in some cases, not being identified until they become life-threatening.
Why Are Māori Men Being Diagnosed Later?
Experts say the reasons are complex and deeply connected to broader health inequities experienced by Māori.
Māori men are less likely to regularly engage with primary healthcare services, often due to cost barriers, limited access to services, work commitments, transport issues and previous negative healthcare experiences.
Without regular contact with a GP, opportunities for conversations about prostate health and screening are reduced.
The Prostate-Specific Antigen (PSA) blood test is commonly used as an early indicator of prostate abnormalities.
Unlike breast, bowel and cervical cancer screening programmes, New Zealand does not currently have a national prostate cancer screening programme. Instead, men generally need to request testing or have the conversation initiated by their doctor.
Health advocates argue this system disadvantages many Māori men, particularly those already facing barriers to healthcare access.
Research has shown Māori men receive PSA testing less frequently than non-Māori men, contributing to later detection and poorer outcomes.
Multiple studies have identified inequities throughout the cancer care pathway.
These include:
- Delays in referrals to specialists
- Delays in diagnostic imaging and biopsies
- Reduced access to advanced treatment options
- Geographic barriers for rural Māori communities
- Lack of culturally safe healthcare environments
For many Māori patients, navigating the health system can be difficult and intimidating, especially when services are not designed around Māori models of health and wellbeing.
The Human Cost
Behind every statistic is a whānau affected by loss, uncertainty and grief.
Prostate cancer does not only impact the individual diagnosed. Partners, children, grandchildren and wider whānau often become caregivers and support networks throughout treatment.
When diagnoses occur late, treatment can become more invasive and survival rates decline. Advanced prostate cancer may require extensive medical intervention, prolonged hospital stays and ongoing palliative care.
The emotional toll can be significant, particularly in communities where men may be reluctant to discuss health concerns or seek medical help early.
The Prostate Cancer Foundation of New Zealand has spent years advocating for a government-funded early detection programme.
Advocates have proposed pilot screening programmes in selected regions to assess how a structured, risk-based screening approach could improve outcomes and reduce deaths. The proposed pilots would include PSA testing, MRI scans and targeted biopsies for at-risk men.
Health experts argue organised screening programmes can detect cancers earlier, before symptoms appear and while treatment remains highly effective.
The Foundation has expressed disappointment after repeated government decisions not to fund proposed pilot programmes despite widespread clinical support and growing concern about prostate cancer mortality.
Many advocates believe Māori communities should be prioritised within any future screening initiative due to the significantly higher mortality rates experienced by Māori men.
The Importance of Culturally Safe Healthcare
Addressing prostate cancer disparities requires more than screening alone.
Experts increasingly emphasise the need for culturally safe healthcare services that recognise Māori values, perspectives and models of wellbeing.
This includes:
- Greater Māori-led healthcare initiatives
- Improved community education around prostate health
- Increased access to Māori health providers
- Better support for whānau involvement in care decisions
- Building trust between healthcare providers and Māori communities
Health leaders argue that improving outcomes requires a healthcare system designed not only to treat disease but also to eliminate barriers that prevent people from accessing care in the first place.
As New Zealand’s population ages, prostate cancer diagnoses are expected to continue increasing. Researchers warn that without significant improvements in early detection and equitable access to treatment, existing disparities could widen further.
For Māori men, the challenge is particularly urgent.
The evidence is clear: Māori men are less likely to receive a diagnosis, yet more likely to die from prostate cancer. This is not simply a medical issue — it is a reflection of broader inequities within the healthcare system.
Improving outcomes will require sustained investment, earlier detection pathways, culturally responsive healthcare services and a commitment to ensuring every man, regardless of ethnicity or postcode, has an equal chance of surviving one of New Zealand’s most common cancers.
The goal is simple but critical: fewer late diagnoses, fewer preventable deaths, and healthier futures for Māori men and their whānau across Aotearoa.
Sources: RNZ reporting on prostate cancer screening funding decisions, Prostate Cancer Foundation NZ statements, international prostate cancer screening research, and New Zealand health data.
